Procter & Gamble Health (PGHL) Fundamentals 2026 — P/E 33.9x, Revenue Analysis | SniperIQ
Procter & Gamble Health (PGHL) is a India-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of ₹11,186 Crore, trading at ₹6718.20 on the BSE. This SniperIQ fundamentals page covers Procter & Gamble Health's valuation (P/E 33.9x, P/B 21.1x), profitability (net margin 23.2%), revenue (₹1,408 Crore in FY2026), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Procter & Gamble Health's market cap?
Procter & Gamble Health (PGHL) has a market capitalization of approximately ₹11,186 Crore, trading at ₹6718.20 on the BSE. Market cap moves with the live share price.
What is Procter & Gamble Health's P/E ratio?
Procter & Gamble Health's trailing twelve-month P/E ratio is 33.9x, with a price-to-book (P/B) of 21.1x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Procter & Gamble Health?
Procter & Gamble Health runs a net profit margin of 23.2%, a gross margin of 65.0%, and an operating margin of 38.1%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Procter & Gamble Health generate?
Procter & Gamble Health reported revenue of ₹1,408 Crore for fiscal year 2026, with net income of ₹327 Crore and earnings per share (EPS) of 196.94. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Procter & Gamble Health pay a dividend?
Procter & Gamble Health offers a trailing dividend yield of about 3.1%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Procter & Gamble Health financially healthy?
Procter & Gamble Health carries a debt-to-equity ratio of 0.02x and a current ratio of 2.18x, with a market beta of 0.23. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Procter & Gamble Health a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Procter & Gamble Health (PGHL) the key facts are: market cap ₹11,186 Crore, P/E 33.9x, revenue ₹1,408 Crore, 52-week range 4699.7-6955. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Procter & Gamble Health's full fundamentals live
Get Procter & Gamble Health's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.